🇺🇸 FDA
Pipeline program

IDE196 (LXS196), IDE196 (LXS196)

IDE196-010

Phase 3 small_molecule active

Quick answer

IDE196 (LXS196), IDE196 (LXS196) for Uveal Melanoma is a Phase 3 program (small_molecule) at IDEAYA Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
IDEAYA Biosciences
Indication
Uveal Melanoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials